When both BRCA1 and BRCA2 alleles are present, they show a selective toxicity to PARPi compared with when one wild-type allele is present.14,16 The discovery of this vulnerability led to significant efforts to develop PARPi to treat cancer patients with mutations in genes involved in the DSB repair pathway. The gene discussed is BRCA2; the disease is cancer.